| scholarly article | Q13442814 |
| P2093 | author name string | Teru Kumagi | |
| Nadya Al-Harthy | |||
| P2860 | cites work | A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results | Q67590480 |
| A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis | Q68505504 | ||
| A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss | Q69721905 | ||
| Trial of penicillamine in advanced primary biliary cirrhosis | Q69887093 | ||
| Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial | Q70542319 | ||
| The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group | Q70590270 | ||
| Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis | Q70670252 | ||
| Time course of histological progression in primary biliary cirrhosis | Q70869710 | ||
| Primary biliary cirrhosis: the prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome | Q71500533 | ||
| Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis | Q71605603 | ||
| The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study | Q71739390 | ||
| A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group | Q71748735 | ||
| Autoimmune associations in primary biliary cirrhosis | Q71859621 | ||
| Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial | Q72136152 | ||
| A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid | Q72189521 | ||
| Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? | Q72511247 | ||
| Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial | Q73026352 | ||
| Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis | Q73090688 | ||
| Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid | Q73401694 | ||
| Primary biliary cirrhosis, sicca complex, and dysphagia | Q73430902 | ||
| Bezafibrate treatment: a new medical approach for PBC patients? | Q73570834 | ||
| The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone | Q73574823 | ||
| Grip strength and subjective fatigue in patients with primary biliary cirrhosis | Q73812037 | ||
| Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis | Q74529900 | ||
| Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy | Q74730516 | ||
| Fatigue in primary biliary cirrhosis | Q77586211 | ||
| Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study | Q77619532 | ||
| Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial | Q77872001 | ||
| Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial | Q78039888 | ||
| Liver transplantation for primary biliary cirrhosis | Q79240270 | ||
| Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis | Q80226933 | ||
| Guidelines for therapy of autoimmune liver disease | Q80372386 | ||
| Primary biliary cirrhosis | Q81246142 | ||
| Ulcerative colitis complicated with primary biliary cirrhosis | Q82039155 | ||
| Prognostic factors and survival analysis of antimitochondrial antibody-positive primary biliary cirrhosis in Chinese patients | Q83627142 | ||
| Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis | Q84227289 | ||
| Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis | Q84441085 | ||
| Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome | Q84441124 | ||
| Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system | Q94054254 | ||
| The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis | Q45247238 | ||
| Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology | Q45687400 | ||
| Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis | Q45839711 | ||
| Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis | Q46049458 | ||
| Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid | Q46126105 | ||
| Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis | Q46227424 | ||
| Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis | Q46408092 | ||
| Natural history of primary biliary cirrhosis | Q46608065 | ||
| The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study | Q46614923 | ||
| Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy | Q46657540 | ||
| Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis | Q46775425 | ||
| Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment | Q46795010 | ||
| Esophagogastric varices as a prognostic factor for the determination of clinical stage in patients with primary biliary cirrhosis | Q47322110 | ||
| Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence | Q48496394 | ||
| The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 | ||
| Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. | Q50535528 | ||
| Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. | Q50684179 | ||
| Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. | Q50694965 | ||
| A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis | Q51586165 | ||
| Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. | Q53527400 | ||
| Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. | Q53711274 | ||
| Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. | Q54032405 | ||
| Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. | Q54316297 | ||
| Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. | Q55044287 | ||
| Primary biliary cirrhosis | Q56428273 | ||
| Autonomic dysfunction in primary biliary cirrhosis correlates with fatigue severity | Q57710875 | ||
| Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis | Q58376775 | ||
| Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis | Q58803462 | ||
| New insights into autoimmune liver diseases | Q59384468 | ||
| Sertraline as a first-line treatment for cholestatic pruritus | Q61480066 | ||
| Azathioprine and prognosis in primary biliary cirrhosis. | Q64903641 | ||
| Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. | Q64974270 | ||
| A prospective controlled trial of azathioprine in primary biliary cirrhosis | Q67479144 | ||
| Primary biliary cirrhosis | Q21202919 | ||
| Methotrexate for primary biliary cirrhosis | Q24235442 | ||
| Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants | Q24633806 | ||
| The peculiar autoimmunity of primary biliary cirrhosis | Q28144212 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Treatment of primary biliary cirrhosis with low-dose weekly methotrexate | Q33384106 | ||
| Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited | Q34146325 | ||
| Farnesoid X receptor agonists for primary biliary cirrhosis | Q34162898 | ||
| Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. | Q34328076 | ||
| Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis | Q34377943 | ||
| Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients | Q34462959 | ||
| Role of plasmapheresis in primary biliary cirrhosis | Q34526543 | ||
| Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis | Q34594429 | ||
| Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches | Q34623557 | ||
| Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience | Q34904107 | ||
| Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years | Q34932835 | ||
| The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences | Q35348722 | ||
| Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment | Q35358467 | ||
| The epidemiology of primary biliary cirrhosis | Q35573904 | ||
| Pruritus and fatigue in primary biliary cirrhosis | Q35573916 | ||
| Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels. | Q35596429 | ||
| Colchicine for primary biliary cirrhosis: a Cochrane Hepato-Biliary Group systematic review of randomized clinical trials | Q36222112 | ||
| Future Treatment Options in PBC. | Q36249692 | ||
| Fenofibrate for patients with asymptomatic primary biliary cirrhosis | Q36502610 | ||
| Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver | Q36714754 | ||
| Animal models of primary biliary cirrhosis | Q36779199 | ||
| Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay | Q37002423 | ||
| Elastography in hepatology | Q37031948 | ||
| Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment | Q37154329 | ||
| Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? | Q37228810 | ||
| Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis | Q37760788 | ||
| Infection as a risk factor in the pathogenesis of primary biliary cirrhosis: pros and cons | Q37836242 | ||
| Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis | Q37855976 | ||
| Smoking, family history and urinary tract infection are associated with primary biliary cirrhosis: A meta-analysis | Q37880222 | ||
| Diagnosis of primary biliary cirrhosis | Q37960963 | ||
| Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments. | Q38552201 | ||
| Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial | Q39533520 | ||
| A novel treatment for refractory primary biliary cirrhosis? | Q40730696 | ||
| The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis | Q40737262 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Natural history of early primary biliary cirrhosis | Q41234807 | ||
| Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis | Q41503491 | ||
| Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid | Q42620850 | ||
| Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis | Q42626384 | ||
| A prospective trial of colchicine for primary biliary cirrhosis | Q42659809 | ||
| Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis | Q43114906 | ||
| Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
| Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis | Q43488392 | ||
| The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice | Q43589988 | ||
| Pediatric-onset primary biliary cirrhosis | Q43599366 | ||
| Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial | Q43766090 | ||
| Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? | Q43807982 | ||
| Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients | Q43903202 | ||
| Randomized trial of chlorambucil for primary biliary cirrhosis. | Q44093311 | ||
| Fenofibrate treatment in patients with primary biliary cirrhosis | Q44110727 | ||
| Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis | Q44487597 | ||
| Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients | Q44617739 | ||
| When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? | Q44797408 | ||
| A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results | Q44825279 | ||
| Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis | Q44966935 | ||
| Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations | Q45010914 | ||
| Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid | Q45245096 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 61-71 | |
| P577 | publication date | 2012-12-04 | |
| P1433 | published in | Hepatic Medicine: Evidence and Research | Q15817012 |
| P1476 | title | Natural history and management of primary biliary cirrhosis | |
| P478 | volume | 4 |
| Q48342063 | A brief review on prognostic models of primary biliary cholangitis |
| Q92864604 | Emerging therapies for PBC |
| Q47111373 | Palmoplantar keratoderma as a presenting sign of primary biliary cirrhosis |
| Q27016114 | Primary biliary cirrhosis is a generalized autoimmune epithelitis |
| Q38359165 | Ultrasound elastography: liver |
Search more.